...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of nephrology. >Prediction of subclinical renal allograft rejection by vascular endothelial growth factor in serum and urine.
【24h】

Prediction of subclinical renal allograft rejection by vascular endothelial growth factor in serum and urine.

机译：血清和尿液中血管内皮生长因子对亚临床肾移植排斥反应的预测。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Until now subclinical renal allograft rejection has only been recognized through a protocol biopsy. The aim of this study was to assess whether measurement of vascular endothelial growth factor (VEGF) in serum and urine could be adopted as a new noninvasive tool to predict subclinical rejection. METHODS: Concentration of VEGF in serum and urine was determined by ELISA in 132 recipients of a renal allograft with stable renal transplant function who were to undergo protocol biopsy and 80 healthy controls. A conventional receiver operating characteristic (ROC) curve was used to determine the sensitivities and specificities for patients with subclinical rejection. RESULTS: Levels of VEGF in serum (126.96 +/- 20.13 pg/mL; 95% confidence interval [95% CI], 83.10-170.83) and urine (16.14 +/- 4.09 ng/mmol creatinine; 95% CI, 7.21-25.06) of 13 patients with subclinical rejection significantly differed from those of 119 patients with no allograft rejection (No-AR) and health controls. The areas underthe ROC curve were 0.771 (95% CI, 0.0.64-0.901) and 0.819 (95% CI, 0.662-0.976), respectively. Levels of VEGF in serum and urine after antirejection therapy (50.45 +/- 6.58 pg/mL and 2.60 +/- 0.83 ng/mmol creatinine, respectively) were lower than those at the time of protocol biopsy. No difference in urinary and serum VEGF expression was observed between cyclosporine and tacrolimus treatment. CONCLUSION: It is first reported that the monitoring of VEGF in serum and urine might be a new noninvasive approach to supplement a protocol biopsy for detection of subclinical rejection.
机译：背景：到目前为止，亚临床肾移植排斥反应仅通过方案活检得以识别。这项研究的目的是评估血清和尿液中血管内皮生长因子（VEGF）的测量是否可以用作预测亚临床排斥反应的一种新的非侵入性工具。方法：采用ELISA法测定了132例肾功能稳定的同种异体肾移植患者的血清和尿液中的VEGF浓度，这些患者将接受方案活检和80名健康对照。使用常规的接收器操作特征（ROC）曲线确定亚临床排斥反应患者的敏感性和特异性。结果：血清（126.96 +/- 20.13 pg / mL; 95％置信区间[95％CI]，83.10-170.83）和尿液（16.14 +/- 4.09 ng / mmol肌酐; 95％CI，7.21- 25.06）中的13例亚临床排斥反应患者与119例没有同种异体排斥反应（No-AR）和健康控制的患者明显不同。 ROC曲线下的面积分别为0.771（95％CI，0.0.64-0.901）和0.819（95％CI，0.662-0.976）。抗排斥治疗后血清和尿液中的VEGF水平（分别为50.45 +/- 6.58 pg / mL和2.60 +/- 0.83 ng / mmol肌酐）低于协议活检时的水平。在环孢霉素和他克莫司治疗之间，未观察到尿和血清VEGF表达的差异。结论：首次报道监测血清和尿液中的VEGF可能是一种新的非侵入性方法，以补充用于检测亚临床排斥反应的方案活检。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号